Literature DB >> 20066422

[Current tumor pathology. Clinical expectations of pathological diagnosis].

W Hiddemann1.   

Abstract

Modern histochemical, immunological, genetic and molecular biological techniques now make precise tumour diagnosis and identification of biological subgroups possible. By detecting molecular and genetic aberrations, subgroups with varying clinical courses can be distinguished and treated in a targeted manner with the use of antibodies or tyrosine kinase inhibitors. This development will lead to even more accurate diagnosis and affect therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066422     DOI: 10.1007/s00292-009-1255-8

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  10 in total

Review 1.  Chromosomal abnormalities in cancer.

Authors:  Stefan Fröhling; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

Review 2.  Current status and perspectives of therapy for acute myeloid leukemia.

Authors:  W Hiddemann; T Büchner
Journal:  Semin Hematol       Date:  2001-07       Impact factor: 3.851

3.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

4.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

5.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  MicroRNA expression, survival, and response to interferon in liver cancer.

Authors:  Junfang Ji; Jiong Shi; Anuradha Budhu; Zhipeng Yu; Marshonna Forgues; Stephanie Roessler; Stefan Ambs; Yidong Chen; Paul S Meltzer; Carlo M Croce; Lun-Xiu Qin; Kwan Man; Chung-Mau Lo; Joyce Lee; Irene O L Ng; Jia Fan; Zhao-You Tang; Hui-Chuan Sun; Xin Wei Wang
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

Review 9.  The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

Authors:  Sebastian Stintzing; Volker Heinemann; Nicolas Moosmann; Wolfgang Hiddemann; Andreas Jung; Thomas Kirchner
Journal:  Dtsch Arztebl Int       Date:  2009-03-20       Impact factor: 5.594

10.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.